Busulfan Combined with Cyclophosphamide as the Conditioning Regimen in Patients with Multiple Myeloma Treated by Autolo-gous Hematopoietic Stem Cell Transplantation.
- Author:
Song JIN
1
;
Yun XU
1
;
Pan-Feng WANG
1
;
Jin ZHOU
1
;
Bin GU
1
;
Wei-Yang LI
1
;
Hui-Fen ZHOU
1
;
Cheng-Cheng FU
2
Author Information
- Publication Type:Journal Article
- MeSH: Busulfan; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Multiple Myeloma; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous
- From: Journal of Experimental Hematology 2015;23(6):1618-1622
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo retrospectively analyze the safety and efficacy of busulfan (BU) combined with cyclophosphamide (CY) as the conditioning regimen of autologous hematopoietic stem cell transplantation (auto-HSCT) in patients with multiple myeloma (MM).
METHODSThe safety and efficacy of the BUCY regimen were evaluated through observing the adverse reactions, recovery of hematopoietic reconstitution, response and survival in 20 patients after auto-HSCT.
RESULTSIn 20 MM patients with median age 52.5 (38-66), the neutrophil and platelet counts recovered at 10(8-18) d and 10 (8-17) d after auto-HSCT respectively, the treatment related mortality during 100 days after auto-HSCT was 0, the partial remission (PR) rate decreased from 31.58% to 0 (P < 0.05) after auto-HSCT, only 1 patient was in progression of disease, all patients were alived.
CONCLUSIONFor patients with MM treated with Auto-HSCT, the BUCY regimen is ideal in safety and response, but the long-term effect still should be observed.
